|
Aug. 13, 2025
| This week’s commercialization news and insights for biopharma leaders
Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis.
|
With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial success that’s eluded many of its peers.
|
UPDATED
One analyst speculated that, going forward, Prasad may be less “heavy-handed” in reviewing rare disease therapies given the public backlash to the agency’s confrontation with Sarepta.
|
The story of the rare disease market in recent years has been centered around growth with large pharmas starting to see more promise in the space as deals tick up. Learn more in
|
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.
|
UPDATED
In its latest earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs.
|
From Our Library
Trendline
Supported by Catalent
|
View all resources
What We're Reading
Reuters
|
Reuters
|
Bloomberg Law
|
Company Announcements
Press releases from companies in your industry.
| 
